InMed Pharmaceuticals Inc. (MTRI) stock
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$15.61+3.41 (+27.94%)
Close on Nov 11, 2026Market cap $85.75MP/E –Yield –
InMed Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
InMed Pharmaceuticals's gross margin for the twelve months ending Dec 31, 2025 was 29.7%. For fiscal 2025 it was 34.5%, against 23.9% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Jun 30, 2025 | 34.5% | +10.6 |
| FY2024 | Jun 30, 2024 | 23.9% | −10.0 |
| FY2023 | Jun 30, 2023 | 33.9% | −16.0 |
| FY2022 | Jun 30, 2022 | 49.9% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | 22.5% | −19.0 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | 36.0% | −3.0 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | 44.2% | +7.9 |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 13.9% | −10.8 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | 41.5% | +15.3 |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 39.0% | +36.7 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | 36.3% | −31.6 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | 24.7% | +6.1 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | 26.1% | −1.8 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | 2.4% | +155.4 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | 68.0% | +19.4 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | 18.6% | −40.3 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | 27.9% | −14.2 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -153.1% | – |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | 48.5% | – |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | 58.9% | – |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | 42.1% | – |
See a number that looks wrong?